Speaker Profile

Eric Miller

Biography
Eric works at the intersection of high-plex proteomics and translational discovery, partnering with leading academic and biopharma groups to implement advanced molecular profiling technologies across oncology, immunology, and complex disease biology. Over the past decade, his collaborative efforts have contributed to studies published in Nature, Nature Genetics, Genome Biology, and Breast Cancer Research, applying new approaches to define tumor microenvironment states, immune programs, and treatment-associated biology. This work has focused on translating high-dimensional molecular data into mechanistic insight and clinically relevant hypotheses. At Nomic, he now concentrates on advancing scalable, quantitative protein profiling to enable large-cohort biomarker discovery, longitudinal monitoring, and mechanism-informed drug development in precision medicine.

---

Talk
High-Throughput Proteomic Profiling of RADIOHEAD Cohort
High cost and low throughput have constrained proteomic studies in cancer immunotherapy to small cohorts, limiting biomarker discovery and validation. In the largest plasma proteomics study of checkpoint inhibitor-treated patients to date, we discuss how Nomic high-throughput protein profiling enables scalable, longitudinal biomarker discovery for response and immune-related adverse events.

Spatial Showcase:
Nomic Bio
Nomic was founded to make biology easier to measure and enable scientists to extend lives by making proteomics accessible, scalable, and routine. The company delivers large-scale, quantitative, and cost-effective protein data through a flexible, end-to-end service—combining customizable content, expert support, and analysis-ready outputs to integrate proteomics seamlessly across drug and biomarker development.